Avidity Biosciences Inc
RNAM
株式のランク
#2068
Avidity Biosciences, Inc. is at the forefront of developing a novel class of... Avidity Biosciences, Inc. is at the forefront of developing a novel class of oligonucleotide-based therapies, known as Antibody Oligonucleotide Conjugates (AOCs). Utilizing its proprietary AOC platform, the company engineers treatments that strategically merge the targeted delivery capabilities of monoclonal antibodies with the precise action of oligonucleotide-based therapeutics. This innovative method aims to reach cell and tissue types previously inaccessible to treatment, thereby more effectively addressing the fundamental genetic causes of various diseases. The company was established on November 13, 2012, by Troy E. Wilson, Kent Hawryluk, Mark E. Davis, and Francis Patrick McCormick, and its main office is located in San Diego, California.
株価
$71.34
最終同期: 2026-03-03
時価総額
$9.84B
変化（1日）
0.00%
変化（1年）
-
国
US
取引 Avidity Biosciences Inc (RNAM)
カテゴリー
Healthcare
Avidity Biosciences Inc（RNAM）のP/S比率
October 2026 時点のP/S比率 TTM: 655.07
Avidity Biosciences Inc の最新の財務報告および株価によると、現在のP/S比率（TTM）は 655.07 です。2024 年末時点でのP/S比率は 743.81 でした。
Avidity Biosciences Inc の P/S 比率の履歴（2018 ～ 2026）
各年末時点のP/S比率
| 年 | P/S比率 | 変化 |
|---|---|---|
| 2026 (TTM) | 655.07 | 22.82% |
| 2025 | 533.36 | -28.29% |
| 2024 | 743.81 | 34.08% |
| 2023 | 554.77 | 35.05% |
| 2022 | 410.78 | 27.30% |
| 2021 | 322.68 | 39.17% |
| 2020 | 231.86 | -80.28% |
| 2019 | 1.18K | -83.65% |
| 2018 | 7.19K | 0.00% |
同業他社のP/S比率
| 企業 | P/S比率 | P/S比率の差 | 国 |
|---|---|---|---|
| 10.02 | -98.47% |
US
|
|
| 41.70 | -93.63% |
US
|
|
| 4.19 | -99.36% |
AU
|
|
| 4.52 | -99.31% |
BE
|
|
| 10.44 | -98.41% |
NL
|
